Skip to main content
Spinal Cord InjuriesProcedureDevice

What this study is

Empower BP is a pivotal, interventional, multicenter, prospective, randomized, controlled double-blinded study to evaluate the safety and effectiveness of the ARC-IM System in managing symptomatic blood pressure instability in individuals with chronic SCI (>1 year after SCI).

The primary effectiveness outcome will be evaluated through subject-reported ADFSCI and seated blood pressure assessments at 3 months post-implant.

Following a baseline screening period and the surgical implantation of the ARC-IM System, subjects will be randomized with a 2:1 ratio into an active or control arm for 3 months. All the subjects will undergo therapy activation sessions (into either Group 1: active intervention, or Group 2: intervention aimed to mimic the active intervention without the active component) within 21 days of the surgical implant and will then commence independent at-home use of ARC-IM Therapy. At the 3 Month timepoint, after all assessments are conducted, all subjects will transition to the open-label period in order to receive the active version of the ARC-IM System in an open-label fashion. All subjects will undergo therapy programming sessions following Month 3.

What's being tested

  • ARC-IM System Implantation

    Intervention · PROCEDURE

    Implantation of the ARC-IM Thoracic Lead in the epidural space and ARC-IM Neurostimulator

  • ARC-IM Therapy (Group 1)

    Intervention · DEVICE

    The ARC-IM System is programmed since day 0 to deliver active electrical spinal cord stimulation at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury

  • ARC-IM Therapy (Group 2)

    Intervention · DEVICE

    The ARC-IM System is programmed at month 3 to deliver active electrical spinal cord stimulation at the low thoracic level for the management of symptomatic blood pressure instability in people with chronic spinal cord injury

Study details

Sponsor
ONWARD Medical, Inc.
Conditions
Spinal Cord Injuries · Blood Pressure Disorders
Enrolling
60 people
Starts
2025-10-17
Est. completion
2029-03
Design
Triple-blind, randomized, crossover
Record
View on ClinicalTrials.gov ↗